Unlocking the Future of CAR T-Cell Therapy: Nexcella Inc. to Present at Prestigious European Medical Conferences
Nexcella, Inc. Announces Poster Presentation at the European Society for Blood and Marrow Transplantation Exciting Updates on NXC-201 CAR-T Therapy LOS ANGELES, CA, Dec. 28, 2022 (GLOBE NEWSWIRE) — Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), a biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology, is set to present…